The short version: SLU-PP-332 has zero human clinical trials, no public IND filing, and no announced commercial development program as of May 2026. It is an academic preclinical compound that has gathered substantial interest in self-experimentation communities and research-peptide markets despite never having been administered to a human in a published study.
Research-context information only. SLU-PP-332 is an investigational small-molecule pan-agonist of the estrogen-related receptors (ERRα/β/γ) developed at Saint Louis University. It is not approved by the FDA and has not entered human clinical trials. The clinical-research status reported below comes from published academic literature, ClinicalTrials.gov, and publicly available patent records. Consult a licensed physician for personal medical decisions.
This article walks through what is documented — the primary literature, the patent estate, the development of the orally active sibling SLU-PP-915, and what would need to happen for SLU-PP-332 to enter a Phase 1 trial.
The Primary Literature — Three Papers Plus an Oral Successor
The SLU-PP-332 record consists of four foundational papers, all from the Burris lab at Saint Louis University. They define what is known about ERR pan-agonism via this compound.
Billon et al., ACS Chemical Biology 2023 (PMID 36988910)
Title: Synthetic ERRα/β/γ agonist induces an ERRα-dependent acute aerobic exercise response and enhances exercise capacity.
Why it matters: This is the discovery paper. It introduces SLU-PP-332 as a synthetic pan-agonist of ERRα/β/γ, shows that it induces an acute aerobic-exercise transcriptional program in skeletal muscle, and demonstrates that treated mice run ~70% longer in time and ~45% farther in distance than vehicle controls. The effect required ERRα — knockouts showed no benefit, ruling out off-target mechanisms.
What the paper does not do: establish a human dose, characterize pharmacokinetics in any species other than mice via IP injection, or measure long-term safety.
Billon et al., J Biological Chemistry 2023 (PMID 37739806)
Title: A synthetic ERR agonist alleviates metabolic syndrome.
Why it matters: This is the metabolic-syndrome paper. DIO mice on 25 mg/kg IP twice daily for 28 days lost ~12% body weight, gained ~10× less fat than vehicle controls on the same high-fat diet, improved glucose tolerance, and increased resting energy expenditure. It is the source of the "fat-loss compound" framing that has driven research-market interest.
What it does not do: test the same protocol in any human, measure bioavailability for any non-IP route, or assess long-term safety beyond 28 days.
Xu et al., Circulation 2023 (PMID 37961903)
Title: Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function.
Why it matters: This is the cardiac-safety and cardiac-efficacy paper. Mouse pressure-overload heart failure was treated with SLU-PP-332 and the related compound SLU-PP-915. Both improved ejection fraction, reduced fibrosis, and improved survival without inducing pathological cardiac hypertrophy. ERRγ was the main mediator. This is the relevant data for the cardiac-safety conversation around chronic ERR pan-agonism.
What it does not do: study cardiac safety in normal animals at chronic exposure, or in humans at any exposure.
Billon et al., J Pharmacology and Experimental Therapeutics 2025 (PMID 41421047)
Title: An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity.
Why it matters: This paper introduces a new compound, SLU-PP-915, as an orally active ERR pan-agonist. The framing is explicit: SLU-PP-915 was developed because the parent compound SLU-PP-332 "lacks oral bioavailability." This is the citation that anchors the route-of-administration discussion in the SLU-PP-332 buying guide and reconstitution guide.
The practical implication: the lab's own development trajectory points toward SLU-PP-915, not SLU-PP-332, as the candidate most likely to progress into a clinical program. SLU-PP-332 may end up as a research tool rather than a drug development candidate.
What Has Not Been Published
For context on how thin the dataset is, here is what does not exist for SLU-PP-332:
- Phase 1 single-ascending-dose study
- Phase 1 multi-ascending-dose pharmacokinetics
- Human pharmacokinetics for any route
- Subcutaneous pharmacokinetics for any species
- Sublingual pharmacokinetics for any species
- Long-term carcinogenicity (lifetime rodent studies)
- Reproductive toxicity
- Drug interaction studies
- Phase 1/2/3 trial in any indication
- An FDA Investigational New Drug (IND) application disclosure
Every "human dose" cited in community references is allometric scaling from the mouse 25 mg/kg IP BID protocol. Every safety claim is extrapolation from the 28-day mouse exposure window.
